{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T08:59:16Z","timestamp":1770541156084,"version":"3.49.0"},"reference-count":69,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDRR"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Oral disintegrating tablets (ODT) offer an attractive choice for Gastroesophageal Reflux\nDisease (GERD) patients suffering from dysphagia. In chronic condition, GERD patient suffers\nfrom severe erosive esophagitis. Thus patients feel difficulty and pain during swallowing,\nwhich results in patient in-compliance toward medication of tablets or capsules- especially in geriatrics\nand pediatric patients. These symptoms of GERD patients have attracted the formulation\nscientists in improving the formulation methodology for such patients. Orally disintegrating tablets\ncould increase the therapeutic impact and drug compliance in these patients. The aim of this\ncompilation is to provide a more convenient way to develop an oral disintegrating drug delivery\nsystem of proton pump inhibitors in patients suffering from odynophagia, associated with chronic\nGastroesophageal Reflux Disease (GERD). Oral disintegrating tablets (ODT), when placed on the\ntongue, can quickly disintegrate and release the medicament. It later dissolves or disperses in saliva\nwithout any additional water. The saliva containing drug can easily be swallowed and descends\ninto the stomach leading to maximum absorption from the mouth, throat, and upper esophagus.\nThe patient compliance and bio-availability of Oral disintegrating tablets (ODT) are high compared\nto other conventional tablets.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2589977515666230221160449","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T06:43:31Z","timestamp":1677221011000},"page":"199-206","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oral Disintegrating Tablets of Proton Pump Inhibitors for Chronic Gastroesophageal\nReflux Disease: An Update"],"prefix":"10.2174","volume":"15","author":[{"given":"Avani","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Hygia Institute of Pharmaceutical Education and Research, Lucknow, U.P., India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juber","family":"Akhtar","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, U.P., India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KC","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Hygia Institute of Pharmaceutical Education and Research, Lucknow, U.P., India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Badruddeen","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, U.P., India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Irfan","family":"Khan","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, U.P., India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, U.P., India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1471-230X-12-66","volume":"12","author":"Yen H.H.","year":"2012","unstructured":"Yen H.H.; Yang C.W.; Su W.W.; Soon M.S.; Wu S.S.; Lin H.J.; Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. BMC Gastroenterol 2012,12(1),66","journal-title":"BMC Gastroenterol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1080\/17425247.2021.2011856","volume":"18","author":"Wiedey R.","year":"2021","unstructured":"Wiedey R.; Kokott M.; Breitkreutz J.; Orodispersible tablets for pediatric drug delivery: current challenges and recent advances. Expert Opin Drug Deliv 2021,18(12),1873-1890","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s10620-005-2962-5","volume":"50","author":"Oda K.","year":"2005","unstructured":"Oda K.; Iwakiri R.; Hara M.; Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig Dis Sci 2005,50(10),1921-1926","journal-title":"Dig Dis Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/BF01537240","volume":"35","author":"Jacob P.","year":"1990","unstructured":"Jacob P.; Kahrilas P.J.; Vanagunas A.; Peristaltic dysfunction associated with nonobstructive dysphagia in reflux disease. Dig Dis Sci 1990,35(8),939-942","journal-title":"Dig Dis Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/nyas.12237","volume":"1300","author":"Johnston N.","year":"2013","unstructured":"Johnston N.; Dettmar P.W.; Strugala V.; Allen J.E.; Chan W.W.; Laryngopharyngeal reflux and GERD. Ann N Y Acad Sci 2013,1300(1),71-79","journal-title":"Ann N Y Acad Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/SGA.0000000000000359","volume":"42","author":"Chen J.","year":"2019","unstructured":"Chen J.; Brady P.; Gastroesophageal reflux disease. Gastroenterol Nurs 2019,42(1),20-28","journal-title":"Gastroenterol Nurs"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.3748\/wjg.v21.i24.7558","volume":"21","author":"H\u00e4gg M.","year":"2015","unstructured":"H\u00e4gg M.; Tibbling L.; Franz\u00e9n T.; Esophageal dysphagia and reflux symptoms before and after oral IQoro R training. World J Gastroenterol 2015,21(24),7558-7562","journal-title":"World J Gastroenterol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3949\/ccjm.87a.19114","volume":"87","author":"Young A.","year":"2020","unstructured":"Young A.; Kumar M.A.; Thota P.N.; GERD: A practical approach. Cleve Clin J Med 2020,87(4),223-230","journal-title":"Cleve Clin J Med"},{"key":"ref=9","year":"2015","unstructured":"Guidance for industry: Size, shape and other physical attributes of generic tablets and capsules. Silver Spring, MD, USA U.S. food and drug administration.2015"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ijpharm.2009.08.010","volume":"382","author":"Okuda Y.","year":"2009","unstructured":"Okuda Y.; Irisawa Y.; Okimoto K.; Osawa T.; Yamashita S.; A new formulation for orally disintegrating tablets using a suspension spray-coating method. Int J Pharm 2009,382(1-2),80-87","journal-title":"Int J Pharm"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2165\/00044011-200727110-00003","volume":"27","author":"de Argila C.M.","year":"2007","unstructured":"de Argila C.M.; Ponce J.; M\u00e1rquez E.; Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease: ACEPTO study. Clin Drug Investig 2007,27(11),765-770","journal-title":"Clin Drug Investig"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/1567201814666170320143824","volume":"15","author":"Agiba A.M.","year":"2018","unstructured":"Agiba A.M.; Abdel-Hamid S.; Nasr M.; Geneidi A.S.; Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and physicomechanical characterization. Curr Drug Deliv 2018,15(2),267-277","journal-title":"Curr Drug Deliv"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/pharmacy8040186","volume":"8","author":"Chinwala M.","year":"2020","unstructured":"Chinwala M.; Recent formulation advances and therapeutic usefulness of Orally Disintegrating Tablets (ODTs). Pharmacy (Basel) 2020,8(4),186","journal-title":"Pharmacy (Basel)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1248\/cpb.58.885","volume":"58","author":"Kakutani R.","year":"2010","unstructured":"Kakutani R.; Muro H.; Makino T.; Development of a new disintegration method for orally disintegrating tablets. Chem Pharm Bull (Tokyo) 2010,58(7),885-890","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1046\/j.1365-2036.2003.01455.x","volume":"17","author":"Freston J.W.","year":"2003","unstructured":"Freston J.W.; Chiu Y.L.; Mulford D.J.; Ballard E.D.; Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003,17(3),361-367","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i6.10","volume":"21","author":"Fu Y.","year":"2004","unstructured":"Fu Y.; Yang S.; Jeong S.H.; Kimura S.; Park K.; Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004,21(6),433-476","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mcna.2018.08.002","volume":"103","author":"Yadlapati R.","year":"2019","unstructured":"Yadlapati R.; DeLay K.; Proton Pump Inhibitor\u2013Refractory Gastroesophageal Reflux Disease. Med Clin North Am 2019,103(1),15-27","journal-title":"Med Clin North Am"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jss.2018.09.036","volume":"235","author":"Walle K.V.","year":"2019","unstructured":"Walle K.V.; Funk L.M.; Xu Y.; Persistent Dysphagia Rate After Antireflux Surgery is Similar for Nissen Fundoplication and Partial Fundoplication. J Surg Res 2019,235,52-57","journal-title":"J Surg Res"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/B978-0-12-801238-3.65937-8","author":"Wang K.K.","year":"2020","unstructured":"Wang K.K.; Gener J.R.; Gastroesophageal reflux disease (GERD). Encyclopedia of gastroenterology 2020,672-681","journal-title":"Encyclopedia of gastroenterology"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1053\/j.sempedsurg.2016.05.009","volume":"25","author":"Barnhart D.C.","year":"2016","unstructured":"Barnhart D.C.; Gastroesophageal reflux disease in children. Semin Pediatr Surg 2016,25(4),212-218","journal-title":"Semin Pediatr Surg"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1001\/jama.2020.21573","volume":"324","author":"Maret-Ouda J.","year":"2020","unstructured":"Maret-Ouda J.; Markar S.R.; Lagergren J.; Gastroesophageal Reflux Disease. JAMA 2020,324(24),2565","journal-title":"JAMA"},{"key":"ref=22","author":"Brunton L.L.","year":"2007","unstructured":"Brunton L.L.; Goodman L.S.; Blumenthal D.; Buxton I.;  Goodman and Gilman\u2019s manual of pharmacology and therapeutics 2007","journal-title":"Goodman and Gilman\u2019s manual of pharmacology and therapeutics"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.mcna.2021.05.013","volume":"105","author":"McCarty E.B.","year":"2021","unstructured":"McCarty E.B.; Chao T.N.; Dysphagia and Swallowing Disorders. Med Clin North Am 2021,105(5),939-954","journal-title":"Med Clin North Am"},{"key":"ref=24","first-page":"1067","volume":"7","author":"Dey N.","year":"2008","unstructured":"Dey N.; Rao S.M.M.; Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res 2008,7,1067-1075","journal-title":"Trop J Pharm Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2036.1995.tb00394.x","volume":"9","author":"Huber R.","year":"1995","unstructured":"Huber R.; Kohl B.; Sachs G.; Senn-Bilfinger J.; Simon W.A.; Sturm E.; The continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995,9(4),363-378","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5009\/gnl16615","volume":"12","author":"Sandhu D.S.","year":"2018","unstructured":"Sandhu D.S.; Fass R.; Current trends in the management of gastroesophageal reflux disease. Gut Liver 2018,12(1),7-16","journal-title":"Gut Liver"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/tcrm.2007.3.2.231","volume":"3","author":"Scholten T.","year":"2007","unstructured":"Scholten T.; Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag 2007,3(2),231-243","journal-title":"Ther Clin Risk Manag"},{"key":"ref=28","author":"Bernshteyn M.A.","year":"2022","unstructured":"Bernshteyn M.A.; Masood U.; Pantoprazole. StatPearls 2022","journal-title":"StatPearls"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/ciia.2007.2.1.85","volume":"2","author":"Calabrese C.","year":"2007","unstructured":"Calabrese C.; Fabbri A.; Febo G.D.; Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging 2007,2(1),85-92","journal-title":"Clin Interv Aging"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S1086-5802(16)31036-1","volume":"40","author":"Welage L.S.","year":"2000","unstructured":"Welage L.S.; Berardi R.R.; Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000,40(1),52-62","journal-title":"J Am Pharm Assoc (Wash)"},{"key":"ref=31","first-page":"37","author":"Anonymous","year":"2010","unstructured":"Anonymous ;  Gastric Acid-Related Diseases and PPIs, Therapeutic trends, canadian pharmaceutical marketing 2010,37-40","journal-title":"Gastric Acid-Related Diseases and PPIs, Therapeutic trends, canadian pharmaceutical marketing"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5152\/tjg.2016.15514","volume":"27","author":"\u00c7elebi A.","year":"2020","unstructured":"\u00c7elebi A.; Aydin D.; Kocaman O.; Konduk B.T.; \u015eent\u00fcrk O.; H\u00fclag\u00fc S.; Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastr\u0131c pH in extensive metabolizer patients with gastroesophageal reflux disease. Turk J Gastroenterol 2020,27(5),408-414","journal-title":"Turk J Gastroenterol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.giec.2019.12.005","volume":"30","author":"Schnoll-Sussman F.","year":"2020","unstructured":"Schnoll-Sussman F.; Niec R.; Katz P.O.; Proton Pump Inhibitors. Gastrointest Endosc Clin N Am 2020,30(2),239-251","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0149-2918(00)83061-1","volume":"22","author":"Avner D.L.","year":"2000","unstructured":"Avner D.L.; Clinical experience with pantoprazole in gastroesophageal reflux disease. Clin Ther 2000,22(10),1169-1185","journal-title":"Clin Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1517\/13543784.6.7.885","volume":"6","author":"Garner A.","year":"1997","unstructured":"Garner A.; Fadlallah H.; Pantoprazole: a new and more specific proton pump inhibitor. Expert Opin Investig Drugs 1997,6(7),885-893","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1111\/j.1572-0241.2000.03254.x","volume":"95","author":"Richter J.E.","year":"2000","unstructured":"Richter J.E.; Bochenek W.; Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Am J Gastroenterol 2000,95(11),3071-3080","journal-title":"Am J Gastroenterol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000070393","volume":"67","author":"Baldi F.","year":"2003","unstructured":"Baldi F.; Malfertheiner P.; Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003,67(1-2),1-5","journal-title":"Digestion"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3109\/10717541003762821","volume":"17","author":"Kadam V.D.","year":"2010","unstructured":"Kadam V.D.; Gattani S.G.; Development of colon targeted multiparticulate pulsatile drug delivery system for treating nocturnal asthma. Drug Deliv 2010,17(5),343-351","journal-title":"Drug Deliv"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2174\/1872211314999201123202930","volume":"14","author":"Sharma S.","year":"2021","unstructured":"Sharma S.; Singh K.; Oral disintegrating tablets \u2013 An updated patent perspective. Recent Pat Drug Deliv Formul 2021,14(3),166-190","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"6618934","DOI":"10.1155\/2021\/6618934","volume":"2021","author":"Ghourichay M.P.","year":"2021","unstructured":"Ghourichay M.P.; Kiaie S.H.; Nokhodchi A.; Javadzadeh Y.; Formulation and quality control of orally disintegrating tablets (ODTs): Recent advances and perspectives. BioMed Res Int 2021,2021,6618934","journal-title":"BioMed Res Int"},{"key":"ref=41","year":"2008","unstructured":"U.S. food and drug administration. Guidance for industry: Orally disintegrating tablets. Silver Spring, MD, USA 2008"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijpharm.2012.03.021","volume":"430","author":"Pabari R.M.","year":"2012","unstructured":"Pabari R.M.; Ramtoola Z.; Application of face centred central composite design to optimise compression force and tablet diameter for the formulation of mechanically strong and fast disintegrating orodispersible tablets. Int J Pharm 2012,430(1-2),18-25","journal-title":"Int J Pharm"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1517\/17460441.2014.941802","volume":"9","author":"Al-khattawi A.","year":"2014","unstructured":"Al-khattawi A.; Mohammed A.R.; Challenges and emerging solutions in the development of compressed orally disintegrating tablets. Expert Opin Drug Discov 2014,9(10),1109-1120","journal-title":"Expert Opin Drug Discov"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1039\/b800209f","volume":"18","author":"Hoon Y.T.","year":"2008","unstructured":"Hoon Y.T.; Yourong F.; Kinam P.; Material properties for making fast dissolving tablets by a compression method. J Mater Chem 2008,18(8),3527-3535","journal-title":"J Mater Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"106019","DOI":"10.1016\/j.ejps.2021.106019","volume":"168","author":"Xu Y.","year":"2022","unstructured":"Xu Y.; Yan G.; Wen X.; Preparation, evaluation, and pharmacokinetics in beagle dogs of a taste-masked flunixin meglumine orally disintegrating tablet prepared using hot-melt extrusion technology and D-optimal mixture design. Eur J Pharm Sci 2022,168,106019","journal-title":"Eur J Pharm Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3109\/03639045.2014.935392","volume":"41","author":"Cantor S.L.","year":"2015","unstructured":"Cantor S.L.; Khan M.A.; Gupta A.; Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydro-chloride. Drug Dev Ind Pharm 2015,41(7),1156-1164","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=47","author":"McLaughlin SB","year":"2009","unstructured":"McLaughlin SB; Orally disintegrating tablets- effect of recent FDA guidance on ODT technologies and application. Pharmaceut Technol Available from: 2009"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1208\/s12249-021-02194-5","volume":"23","author":"Nakamura S.","year":"2022","unstructured":"Nakamura S.; Fukai T.; Sakamoto T.; Orally disintegrating tablet manufacture via direct powder compression using cellulose nanofiber as a functional additive. AAPS PharmSciTech 2022,23(1),37","journal-title":"AAPS PharmSciTech"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e08956","DOI":"10.1016\/j.heliyon.2022.e08956","volume":"8","author":"Agrawal S.","year":"2022","unstructured":"Agrawal S.; Fernandes J.; Shaikh F.; Patel V.; Quality aspects in the development of pelletized dosage forms. Heliyon 2022,8(2),e08956","journal-title":"Heliyon"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4274\/tjps.galenos.2018.99266","volume":"16","author":"Salve V.","year":"2019","unstructured":"Salve V.; Mishra R.; Nandgude T.; Development and optimization of a floating multiparticulate drug delivery system for norfloxacin. Turkish. J Pharmaceut Sci 2019,16(3),326-334","journal-title":"J Pharmaceut Sci"},{"key":"ref=51","first-page":"327","volume":"9","author":"Asghar L.F.","year":"2006","unstructured":"Asghar L.F.; Chandran S.; Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J Pharm Pharm Sci 2006,9(3),327-338","journal-title":"J Pharm Pharm Sci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"105019","DOI":"10.1016\/j.ejps.2019.105019","volume":"138","author":"Maderuelo C.","year":"2019","unstructured":"Maderuelo C.; Lanao J.M.; Zarzuelo A.; Enteric coating of oral solid dosage forms as a tool to improve drug bioavailability. Eur J Pharm Sci 2019,138,105019","journal-title":"Eur J Pharm Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4103\/0250-474X.44597","volume":"70","author":"Ali J.","year":"2008","unstructured":"Ali J.; Rahman M.A.; Development and in vitro evaluation of enteric coated multiparticulate system for resistant tuberculosis. Indian J Pharm Sci 2008,70(4),477-481","journal-title":"Indian J Pharm Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2174\/187221110793237574","volume":"4","author":"AlHusban F.A.","year":"2010","unstructured":"AlHusban F.A.; El-Shaer A.M.; Jones R.J.; Mohammed A.R.; Recent patents and trends in orally disintegrating tablets. Recent Pat Drug Deliv Formul 2010,4(3),178-197","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0378-5173(96)04631-5","volume":"143","author":"Beckert T.E.","year":"1996","unstructured":"Beckert T.E.; Lehmann K.; Schmidt P.C.; Compression of enteric-coated pellets to disintegrating tablets. Int J Pharm 1996,143(1),13-23","journal-title":"Int J Pharm"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1517\/17425247.2013.769955","volume":"10","author":"Al-khattawi A.","year":"2013","unstructured":"Al-khattawi A.; Mohammed A.R.; Compressed orally disintegrating tablets: excipients evolution and formulation strategies. Expert Opin Drug Deliv 2013,10(5),651-663","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0939-6411(96)00028-8","volume":"43","author":"Bodmeier R.","year":"1997","unstructured":"Bodmeier R.; Tableting of coated pellets. Eur J Pharm Biopharm 1997,43(1),1-8","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-642-20195-0_4","volume":"205","author":"Breitkreutz J.","year":"2011","unstructured":"Breitkreutz J.; Boos J.; Drug delivery and formulations. Handb Exp Pharmacol 2011,205,91-107","journal-title":"Handb Exp Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1208\/s12249-011-9626-x","volume":"12","author":"Garg Y.","year":"2011","unstructured":"Garg Y.; Pathak K.; Design and in vitro performance evaluation of purified microparticles of pravastatin sodium for intestinal delivery. AAPS PharmSciTech 2011,12(2),673-682","journal-title":"AAPS PharmSciTech"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0939-6411(02)00117-0","volume":"54","author":"Debunne A.","year":"2002","unstructured":"Debunne A.; Vervaet C.; Remon J.P.; Development and in vitro evaluation of an enteric-coated multiparticulate drug delivery system for the administration of piroxicam to dogs. Eur J Pharm Biopharm 2002,54(3),343-348","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=61","author":"Combessis D.","year":"2006","unstructured":"Combessis D.; Corvaisier D.; Gil A.; Guerin E.; Pharmaceutical formulation and process for its preparation. 2006"},{"key":"ref=62","author":"Chansanroj K.","year":"2010","unstructured":"Chansanroj K.;  Enteric coating of pharmaceutical products Glatt International Times Available from: 2010","journal-title":"Enteric coating of pharmaceutical products Glatt International Times"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0378-5173(94)00169-6","volume":"113","author":"Felton L.A.","year":"1995","unstructured":"Felton L.A.; Haase M.M.; Shah N.H.; Physical and enteric properties of soft gelatin capsules coated with eudragit\u00ae L 30 D-55. Int J Pharm 1995,113(1),17-24","journal-title":"Int J Pharm"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/03639045.2019.1698596","volume":"46","author":"Szczepanska M.","year":"2020","unstructured":"Szczepanska M.; Paduszynski P.; Kotlowska H.; Sznitowska M.; Optimization of the coating process of minitablets in two different lab-scale fluid bed systems. Drug Dev Ind Pharm 2020,46(1),31-41","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1248\/cpb.51.942","volume":"51","author":"Shimizu T.","year":"2003","unstructured":"Shimizu T.; Nakano Y.; Morimoto S.; Tabata T.; Hamaguchi N.; Igari Y.; Formulation study for lansoprazole fast-disintegrating tablet. I. Effect of compression on dissolution behavior. Chem Pharm Bull (Tokyo) 2003,51(8),942-947","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ejpb.2009.07.001","volume":"73","author":"Aguilar-D\u00edaz J.E.","year":"2009","unstructured":"Aguilar-D\u00edaz J.E.; Garc\u00eda-Montoya E.; P\u00e9rez-Lozano P.; Su\u00f1e-Negre J.M.; Mi\u00f1arro M.; Tic\u00f3 J.R.; The use of the SeDeM Diagram expert system to determine the suitability of diluents\u2013disintegrants for direct compression and their use in formulation of ODT. Eur J Pharm Biopharm 2009,73(3),414-423","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ejpb.2011.05.014","volume":"79","author":"AlHusban F.","year":"2011","unstructured":"AlHusban F.; Perrie Y.; Mohammed A.R.; Formulation of multiparticulate systems as lyophilised orally disintegrating tablets. Eur J Pharm Biopharm 2011,79(3),627-634","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"113840","DOI":"10.1016\/j.addr.2021.113840","volume":"178","author":"Sohail Arshad M.","year":"2021","unstructured":"Sohail Arshad M.; Zafar S.; Yousef B.; A review of emerging technologies enabling improved solid oral dosage form manufacturing and processing. Adv Drug Deliv Rev 2021,178,113840","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=69","author":"John P","year":"2004","unstructured":"John P; Bergstrand A; L\u00f6vgren KI;  Multiple unit pharmaceutical preparation containing proton pump inhibitor 2004","journal-title":"Multiple unit pharmaceutical preparation containing proton pump inhibitor"}],"container-title":["Current Drug Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2589977515666230221160449","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213869\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2589977515666230221160449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T03:45:54Z","timestamp":1692675954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213869\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2589977515666230221160449","relation":{},"ISSN":["2589-9775"],"issn-type":[{"value":"2589-9775","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}